1Downs JR, Clearfield M, Whitney E, et al. Pd- mary prevention of acute coronary events with lovastatin in men and women with average cho- lesterol levels [ J ]. JAMA, 1998 : 1615 - 1622.
2Castilla Guerra L, DeI Carmen Fernandez Moreno M. Lopez Chozas JM. et al. Statins in stroke prevention: What an internist should know [ J ]. Eur JIntemMexl,2008 ,19 :8 - 14.
5Bakker - Arkema RG,Best J,Fayyad R,et al+ A brief review paper of the efficacy and safety of atorvastatin in early clinical trials [ J ]. Ath- erosclerosis, 1997,131 ( 1 ) : 13 - 17.
5[1]Endo A,Kuroda M,Tsujita Y.ML-236A,ML-236B,and ML-236C,new inhibitors of cholesterogenesis produced by penicillium citrinium[J].J Antibiot,1976,29:1346-1348
6[2]Amarenco P,Labreuche J,Lavallee P,et al.Statins in stroke prevention and carotid atherosclerosis:systematic review and up-to-date meta-analysis[J].Stroke,2004,35:2902-2909
7[3]Ridker PM,Cannon CP,Morrow D,et al.C-reactive protein levels and outcomes after statin therapy[J].N Engl J Med,2005,352:20-28
8[4]LaRosa JC,Grundy SM,Waters DD,et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease[J].N Engl J Med,2005,352:1425-1435
9[5]Amarenco P.Hypercholesterolemia,lipid-lowering agents,and the risk for brain infarction[J].Neurology,2001,57(Suppl 2):S35-S44
10[6]Aikawa M,Rabkin E,Sugiyama S,et al.An HMG-CoA reductase inhibitor,cerivastatin,suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro[J].Circulation,2001,103:276-283
